Stem Cell Clinic

Sickle Cell Disease Association of America and Aruvant Sciences Forge New Partnership to Educate Around Gene Therapy – Herald-Mail Media

By adminOctober 13, 2020Adult Stem Cells

HANOVER, Md. and NEW YORK, Oct. 12, 2020 /PRNewswire/ -- The Sickle Cell Disease Association of America (SCDAA) and Aruvant Sciences are proud to announce a new partnership to create educational programs to increase awareness of gene therapy as a potential curative treatment option for sickle cell disease patients. This collaboration will help SCDAA continue to deliver on its mission, while assisting Aruvant in learning more about the needs of sickle cell disease (SCD) patients. Under the agreement, Aruvant will collaborate with SCDAA to host local and national educational events and develop materials for a public-awareness campaign.

"In partnership with SCDAA, we are working to educate patients about gene therapy, while gaining critical insights from the patient community for our ARU-1801 SCD development program," said Will Chou, M.D., chief executive officer (CEO) of Aruvant. "Now is a perfect time to work with SCDAA to educate the community about gene therapy since we have an open and enrolling phase 1/2 clinical trial for our potentially curative experimental gene therapy, ARU-1801."

Sickle cell disease affects 100,000 individuals in the United States, disproportionately affecting African Americans with one in 500 African Americans suffering from the disease. This inherited disease affects the production of hemoglobin, a protein in red blood cells that carries oxygen throughout the body. The disease occurs when people inherit a mutation from each of their parents which causes people with SCD to not have normal, healthy adult hemoglobin in their red blood cells and instead have an abnormal hemoglobin called sickle hemoglobin. SCD can cause frequent episodes of severe pain, weakness and other serious complications. Fetal hemoglobin is an "anti-sickling" hemoglobin that is present before birth in the red blood cells. After birth, the gene that makes fetal hemoglobin turns off, which mostly stops the production of fetal hemoglobin. More fetal hemoglobin in the blood can mean fewer episodes of sickling and pain.

"In partnership with Aruvant, we can provide the critical education needed for our community to understand gene therapy and how these promising new treatments work to treat and maybe cure this genetic disease that impacts so many in our community," said Beverley Francis-Gibson, SCDAA president and CEO. "Partnering with companies like Aruvant is critical to help us support the research that could change the lives of many sickle cell disease patients."

Aruvant and SCDAA's educational events will review gene therapy and ongoing research, including discussion around Aruvant's MOMENTUM study. This clinical trial is examining a one-time investigational treatment, ARU-1801, to increase levels of fetal hemoglobin in patients with severe sickle cell disease, with the hope of fewer episodes of sickling and pain. Aruvant provided funding for SCDAA's 48th Annual National Convention 2020 which begins tomorrow, October 13, and will continue through October 17. To register, please visit https://bit.ly/SCDAA2020Convention.

The MOMENTUM StudyAruvant is currently conducting the MOMENTUM study, which is evaluating ARU-1801, a one-time only potentially curative gene therapy for patients with SCD. The MOMENTUM study is currently enrolling, and more information may be found at http://www.momentumtrials.com.

About Sickle Cell Disease Association of AmericaSickle Cell Disease Association of America advocates for people affected by sickle cell conditions and empowers community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure. The association and more than 50 member organizations support sickle cell research, public and professional health education and patient and community services. Visit http://www.sicklecelldisease.org.

About Aruvant SciencesAruvant Sciences, part of the Roivant family of companies, is a clinical-stage biopharmaceutical company focused on developing and commercializing gene therapies for the treatment of rare diseases, with an initial focus on helping patients suffering from sickle cell disease. The company's lead candidate, ARU-1801, is an investigational lentiviral gene therapy for sickle cell disease. ARU-1801 incorporates a patented modified gamma-globin into autologous stem cells, with the aim of restoring normal red blood cell function through increased levels of fetal hemoglobin. The high potency of the modified gamma globin enables ARU-1801 engraftment with only reduced intensity conditioning (RIC). Preliminary clinical data from an ongoing Phase 1/2 study in patients with sickle cell disease demonstrated continuing durable reductions in disease burden. For more information on the clinical study, please visit http://www.momentumtrials.com and for more on the company, please visitwww.aruvant.com.

Caliber Pain is Featured as a 2020 Top NYC Patient Rated Pain Management Practice by Find Local Doctors – PR Web

By adminOctober 10, 2020Stem Cell Medical Center

I am truly dedicated to helping my patients decrease pain, improve mobility and increase their overall quality of life. Being recognized by Find Local Doctors as a 2020 Top Patient Rated Doctor is such a huge honor, says Dr. Michael Fakhry

NEW YORK (PRWEB) October 09, 2020

Caliber Pain is New York Citys leading pain management practice, specializing in customized solutions for musculoskeletal pain and mobility issues. These board-certified physicians, led by Dr. Michael Fakhry, employ a multidisciplinary approach combined with the latest non-surgical, evidence-based interventional procedures at their state-of-the-art AAAHC accredited facility in Manhattan. Caliber Pain has gained the attention of Find Local Doctors for the consistent, exceptional reviews they have received from patients. An easy-to-navigate online directory, Find Local Doctors helps consumers connect with local physicians who are highly-qualified and reputable.

Caliber Pain offers interventional treatments and regenerative medicine for a wide variety of injuries and pain issues and are committed to using a multidisciplinary approach to treating patients. They focus on each individual patients needs and goals, from restoring simple mobility issues to the relief of chronic and complex pain conditions. The medical team creates well-rounded treatment plans that include multiple disciplines and procedures, combining injection therapy such as PRP and STEM cell regenerative treatments), ketamine infusions, physical therapy, nerve blocks, spinal cord stimulation and other options to ensure patients have short and long-term pain management. The experienced specialists at Caliber Pain utilize the latest medical technology and work closely with patients, from the initial diagnosis to mapping out an effective treatment program. Many reviews of this practice have mentioned the highly knowledgeable, compassionate staff and the attentive care they received.

More about Dr. Michael Fakhry:

Dr. Michael Fakhry is an interventional pain management specialist who is double board-certified in anesthesiology and pain medicine. Dr. Fakhry graduated from the accelerated BA/MD joint program with Rutgers University and Robert Wood Johnson Medical School. He then completed his residency in anesthesiology at NYU Medical Center in Manhattan. Following his residency, he completed his fellowship in interventional pain management at NYU where he trained at both academic and public hospitals. Dr. Fakhry is a leader in his field and has published research in numerous medical journals and presented at national and international conferences. Caliber Pain is located at 737 Park Avenue 1C in New York, NY, and can provide a same day diagnosis and interventional pain treatments. Call (212) 203-5987, or visit http://www.caliberpain.com today to schedule your appointment for effective pain management.

Share article on social media or email:

Read the rest here:
Caliber Pain is Featured as a 2020 Top NYC Patient Rated Pain Management Practice by Find Local Doctors - PR Web

Report of the president: Appointments and promotions | Stanford News – Stanford University News

By adminOctober 10, 2020Stem Cell Medical Center

APPOINTMENTS WITHOUT LIMIT OF TIME:

DeSimone, Joseph, Professor of Radiology and of Chemical Engineering, effective September 1, 2020

Hernandez-Boussard, Tina, Associate Professor of Medicine, and by courtesy, of Surgery, effective November 1, 2020

Rose, Sherri, Associate Professor of Medicine, effective August 1, 2020.

Setsompop, Kawin, Associate Professor of Radiology, effective November 1, 2020

PROMOTIONS WITHOUT LIMIT OF TIME:

Bauer, Andrew, Associate Professor of Anthropology, effective September 1, 2020

Collins, Steven, Associate Professor of Mechanical Engineering, effective November 1, 2020

Dixon, Scott, Associate Professor of Biology, effective January 1, 2021

Feng, Liang, Associate Professor of Molecular and Cellular Physiology, effective October 1, 2020

Goldbogen, Jeremy, Associate Professor of Biology, effective January 1, 2021

Gweon, Hyowon, Associate Professor of Psychology, effective September 1, 2020

Huh, June, Professor of Mathematics, effective September 1, 2020

Pasa, Sergiu, Associate Professor of Psychiatry and Behavioral Sciences, effective August 1, 2020

Rivas-Davila, Juan, Associate Professor of Electrical Engineering, effective September 1, 2020

Seetah, Krish, Associate Professor of Anthropology, effective August 1, 2020

Simard, Julia, Associate Professor of Epidemiology and Population Health, and by courtesy, of Medicine, effective January 1, 2021

Stanford, Douglas, Associate Professor of Physics, effective September 1, 2020

Yan Xia, Associate Professor of Chemistry, effective September 1, 2020

PROMOTION FOR A CONTINUING TERM:

Srivastava, Sakti, Professor (Teaching) of Surgery, effective October 1, 2020

OTHER APPOINTMENTS:

Achour, Sara, Assistant Professor (subject to Ph.D.) of Computer Science, for the period September 1, 2020 through August 31, 2024

Allende Santa Cruz, Claudia, Assistant Professor of Economics in the Graduate School of Business, for the period July 1, 2021 through June 30, 2025

Banik, Steven, Assistant Professor of Chemistry, for the period September 1, 2021 through August 31, 2025

Bouland, Adam, Assistant Professor of Computer Science, for the period September 1, 2020 through August 31, 2024

Chaudhari, Akshay, Assistant Professor (Research) of Radiology, for the period October 1, 2020 through September 30, 2024, coterminous with continued salary and research funding from sponsored projects

Clark, Susan, Assistant Professor of Physics, for the period September 1, 2021 through August 31, 2025

Fletcher, Brian, Associate Professor (Teaching) of Law, for the period September 1, 2020 through August 31, 2023

Geldsetzer, Pascal, Assistant Professor of Medicine, for the period November 1, 2020 through October 31, 2024

Kasowski, Maya, Assistant Professor of Medicine and of Pathology, and by courtesy, of Genetics, for the period July 1, 2020 through June 20, 2024

Kozleski, Elizabeth, Professor (Research) of Education, for the period August 31, 2020 through August 30, 2025, coterminous with continued salary and research funding from sponsored projects

Liu, Fang, Assistant Professor of Chemistry, for the period September 1, 2020 through August 31, 2024

Mason, Daniel, Assistant Professor of Psychiatry and Behavioral Sciences, for the period October 1, 2020 through September 30, 2024

Sharaf, Naima, Assistant Professor of Biology, for the period September 1, 2021 through August 31, 2025

Trivedi, Mudit, Assistant Professor (subject to Ph.D.) of Anthropology, for the period July 1, 2021 through June 30, 2025

OTHER PROMOTIONS:

Blanchet, Jose, Professor of Management Science and Engineering, effective September 1, 2020

Gipper, Brandon, Associate Professor of Accounting in the Graduate School of Business, for the period July 1, 2020 through June 30, 2023

Hbert, Benjamin, Associate Professor of Finance in the Graduate School of Business, for the period August 1, 2020 through July 31, 2023

Heilshorn, Sarah, Professor of Materials Science and Engineering, and by courtesy, of Chemical Engineering and of Bioengineering, effective August 1, 2020

Spakowitz, Andrew, Professor of Chemical Engineering and of Materials Science and Engineering, effective September 1, 2020

Yang, Peter, Professor of Orthopaedic Surgery, effective October 1, 2020

OTHER REAPPOINTMENTS:

Auclert, Adrien, Assistant Professor of Economics, for the period July 1, 2023 through June 30, 2024

Bacchetta, Rosa, Associate Professor (Research) of Pediatrics, for the period August 1, 2020 through April 30, 2025, coterminous with continued salary and research funding from sponsored projects

Baiocchi, Michael, Assistant Professor of Epidemiology and Population Health and, by courtesy, of Statistics and of Medicine, for the period September 1, 2021 through August, 2022

Battiato, Ilenia, Assistant Professor of Earth System Science, for the period September 1, 2020 through August 31, 2023

Bernert, Rebecca, Assistant Professor of Psychiatry and Behavioral Sciences, for the period October 1, 2021 through September 30, 2022

Bocolo, Luigi, Assistant Professor of Economics, for the period August 1, 2022 through July 31, 2023

Boettiger, Alistair, Assistant Professor of Developmental Biology, for the period September 1, 2020 through August 31, 2023

Brandman, Onn, Assistant Professor of Biochemistry, for the period September 1, 2020 through November 30, 2020

Chan, David, Assistant Professor of Medicine, for the period November 1, 2022 through October 31, 2023

Chaudhuri, Ovijit, Assistant Professor of Mechanical Engineering, for the period August 1, 2020 through September 30, 2020

Clement, Julien, Assistant Professor of Organizational Behavior in the Graduate School of Business, for the period July 17, 2022 through July 16, 2023

Cuesta Rodriguez, Jos, Assistant Professor of Economics, for the period July 1, 2024 through June 30, 2026

Dubra, Alfredo, Associate Professor of Ophthalmology, for the period September 1, 2020 through August 31, 2021

Duncan, Laramie, Assistant Professor of Psychiatry and Behavioral Sciences, for the period September 1, 2022 through August 31, 2023

Dunn, Laura, Professor of Psychiatry and Behavioral Sciences, for the period September 1, 2020 through November 30, 2020

Dylan, Dodd, Assistant Professor of Pathology and of Microbiology and Immunology, for the period August 16, 2022 through August 15, 2023

Ellsworth, William, Professor (Research) of Geophysics, for the period October 4, 2020 through October 3, 2025, coterminous with continued salary and research funding from sponsored projects

Feldman, Brian, Assistant Professor of Physics, for the period September 1, 2021 through December 31, 2021

Fetter, Dan, Assistant Professor of Economics, for the period July 1, 2024 through June 30, 2025

Frock, Richard, Assistant Professor of Radiation Oncology, for the period January 1, 2022 through December 31, 2022

Fung, Lawrence, Assistant Professor of Psychiatry and Behavioral Sciences, for the period July 1, 2023 through June 30, 2024

Gao, Xiaojing, Assistant Professor of Chemical Engineering, for the period April 1, 2024 through March 31, 2025

Garcia, Antero, Assistant Professor of Education, for the period January 1, 2021 through December 31, 2023

Gorle, Catherine, Assistant Professor of Civil and Environmental Engineering, for the period July 1, 2020 through June 30, 2024

Grillet, Nicolas, Assistant Professor of Otolaryngology Head and Neck Surgery, for the period April 1, 2023 through March 31, 2024

Gross, Eric, Assistant Professor of Anesthesiology, Perioperative and Pain Medicine, for the period September 1, 2021 through August 31, 2022

Gu, Xun, Assistant Professor of Mechanical Engineering and, by courtesy, of Materials Science and Engineering, for the period June 1, 2022 through May 31, 2023

Heaney, Catherine, Associate Professor (Teaching) of Psychology and of Medicine, for the period July 1, 2020 through June 30, 2025

Hebert, Benjamin, Associate Professor of Finance in the Graduate School of Business, for the period August 1, 2023 through July 31, 2024

Hoffman, Mark, Assistant Professor of Sociology, for the period October 16, 2023 through October 15, 2024

Honigsberg, Colleen, Associate Professor of Law, for the period June 1, 2023 through May 31, 2025

Hu, Yang, Assistant Professor of Ophthalmology, for the period December 1, 2020 through November 30, 2021

Huang, Possu, Assistant Professor of Bioengineering, for the period October 1, 2020 through August 31, 2022

Huang, Ting Ting, Associate Professor (Research) of Neurology and Neurological Sciences, for the period November 1, 2020 through October 31, 2021, coterminous with continued salary and research funding from sponsored projects

Iyer, Usha, Assistant Professor of Art and Art History, for the period June 1, 2023 through May 31, 2024

Jagannathan, Prassana, Assistant Professor of Medicine and of Microbiology and Immunology, for the period January 1, 2021 through December 31, 2023

Jaiswal, Siddhartha, Assistant Professor of Pathology, for the period November 1, 2021 through October 31, 2022

Kaltschmidt, Julia, Associate Professor of Neurosurgery, for the period April 1, 2021 through March 31, 2022

Kantor, Roanne, Assistant Professor of English, for the period July 1, 2022 through June 30, 2023

Kasowski, Maya, Assistant Professor of Medicine, and by courtesy, of Genetics, for the period July 1, 2024 through June 30, 2025

Keca, Srdan, Assistant Professor of Art and Art History, for the period September 1, 2023 through August 31, 2024

Konermann, Silvana, Assistant Professor of Biochemistry, for the period October 1, 2023 through September 30, 2024

Konings, Alexandra, Assistant Professor of Earth System Science, for the period September 1, 2020 through August 31, 2023

Kronengold, Charles, Assistant Professor of Music, for the period January 1, 2021 through June 30, 2022

Kundaje, Anshul, Assistant Professor of Genetics and of Computer Science, for the period December 1, 2020 through November 30. 2022

Kwon, Marci, Assistant Professor of Art and Art History, for the period August 1, 2023 through July 31, 2024

Larson, Bradley, Assistant Professor of Economics, for the period August 1, 2023 through July 30, 2024

Linderman, Scott, Assistant Professor of Statistics, for the period June 1, 2023 through May 31, 2025

Long, Jonathan, Assistant Professor of Pathology, for the period January 1, 2023 through December 1, 2023

Mai, Danielle, Assistant Professor of Chemical Engineering, for the period January 1, 2024 through December 31, 2024

Mannix, Andrew, Assistant Professor of Materials Science and Engineering, for the period August 1, 2024 through July 31, 2025

Martinez-Martin, Nicole, Assistant Professor (Research) of Pediatrics, for the period December 1, 2023 through November 30, 2024, coterminous with continued salary and research funding from sponsored projects

Morten, Melanie, Assistant Professor of Economics, for the period July 1, 2021 through June 30, 2022

Mross, Michaela, Assistant Professor of Religious Studies, for the period September 1, 2023 through August 31, 2024

Newman, Aaron, Assistant Professor of Biomedical Data Science, for the period August 1, 2021 through July 31, 2022

Palacios, Julia, Assistant Professor of Statistics and of Biomedical Data Science, for the period September 1, 2021 through August 31, 2024

Read the original here:
Report of the president: Appointments and promotions | Stanford News - Stanford University News

UTSW Scientist: ‘We Need More Women Thinking Creatively in the Lab and Pushing Science Forward’ – dallasinnovates.com

By adminOctober 10, 2020Stem Cell Medical Center

[Image: Oleksandr Bushko/istockphoto]

Its rare to have a woman winning a Nobel Prize, much less two women on the same day and three in the same year, a UTSW spokesperson told us as the news rolled out about this years winners.

American biochemist Jennifer Doudna and French Emmanuelle Charpentier became the first women to jointly win the Nobel Prize in Chemistry on Tuesday. They are the sixth and seventh women to ever win that prize. American astrophysicist Andrea Ghez, along with two others, won the Nobel Prize in physics for their discoveries about black holes on Monday.

UTSW scientist Eric Olson spent the day on a Zoom call with Nobel Prize winner Doudna earlier this week. Olson, who uses CRISPR technology in studies that might one day repair many of the mutations that cause Duchenne muscular dystrophy, called the prize great news.

Doudna and her colleague Charpentier have revolutionized science, biotechnology, and medicine with the development of CRISPR as a gene-editing tool, says Olson, who is the director of UTSWs Hamon Center for Regenerative Science and Medicine and professor and chair of molecular biology.

UT Southwesterns Dr. Eric Olson works with longtime collaborator Dr. Jay Schneider, an adjunct associate professor of internal medicine-cardiology. [Photo: UTSW]

CRISPR forms the basis of a primitive bacterial immune system, which they cleverly adapted to modify the genomes of any organism in a simple and efficient manner, Olson explains.

There are many ways CRISPR gene editing can benefit humanity, he says. The technology is already enabling the elimination of genetic mutations that cause devastating human diseases, Olson says. The breakthrough discovery of Doudna and Charpentier exemplifies the power of basic science to change the world in powerful ways.

The UTSW professor also co-founded Exonics Therapeutics, a Massachusetts-based biotech company that uses CRISPR technology licensed from UT Southwestern Medical Center in Dallas, that acquired in 2019 by Vertex Pharmaceuticals in a deal roughly valued at $1 billion. The scientist launched Exonics in February 2017 to advance and commercialize his research. The company develops treatments for Duchenne muscular dystrophy and other genetic neuromuscular diseases.

Olson works with Professor Rhonda Bassel-Duby, Ph.D., a highly cited researcher who helps run the Olson laboratory.

UT Southwestern Professor Rhonda Bassel-Duby [Photo: UTSW]

Bassel-Duby says its wonderful that the Nobel Prize in Chemistry was awarded to two woman who richly deserve the prize. She hopes the award encourages young women to consider a career in science: Doing scientific research is one of the most enriching and fulfilling professions. We need more women thinking creatively in the lab and pushing science forward, Bassel-Duby says.

Olson and Bassel-Duby work alongside longtime collaborator Jay Schneider, an M.D. and Ph.D. who is an adjunct associate professor of internal medicine-cardiology.

Olson holds the Annie and Willie Nelson Professorship in Stem Cell Research, the Pogue Distinguished Chair in Research on Cardiac Birth Defects, and The Robert A. Welch Distinguished Chair in Science.

Take a look back on the stories that grabbed our readers' attention last month.

FusionFlight, which received a $50,000 seed investment in 2016, has built and tested "the world's smallest and most powerful jet-powered drone with vertical take-off and landing capabilities."

There are plenty of things to do withyourphysically distanced time. Here are a few from our curated selection.

Taysha Gene Therapies, which has been operating in stealth with UT Southwestern, is off to a fast start with a pipeline of 15 gene therapy programs. Together with UTSW, the combined platform could be"an engine for new cures."

Taysha Gene Therapies, which was been operating in stealth with UT Southwestern until this April, plans to use the financing to advance its initial cohort of lead programs into its clinic. By the end of 2021, Taysha expects to file four Investigational New Drug applications.

Everything you need to know about the Kim Kardashian vampire facial – Emirates Woman

By adminOctober 10, 2020Platelet Rich Plasma Injections

Octobers The Bravery Issue Download Now In terms of beauty, other than going under the knife it doesnt get much braver than the vampire facial.

PRP is the term often used for the increasingly popular platelet-rich plasma facial rejuvenation treatment. As the cosmetic industry has continued to develop, you no longer need to go under the knife to see amazing results. Treatments involving lasers and injections can still be daunting however, especially if youre using these for the first time. Platelet Rich Plasma facial rejuvenation treatment (PRP) is one such treatment, commonly referred to as the vampire facial which was made famous by Kim Kardashian in 2013. Aptly named, as the treatment requires blood to be drawn, then put through a special machine to separate the red cells from the nutrient-rich and regenerative plasma. This plasma is then injected into the facial skin, where it is supposedly meant to encourage collagen production and soften fine lines.

Its an incredibly popular treatment globally, which is reflected in the increase in treatment requests within the UAE. American Board Certified Dermatologist Dr Lana Kashlan of CosmeSurge Dubai has witnessed this increase directly. While the sight of the so-called vampire facial can be daunting, Dr Kashlan actually says its one of the safest treatments you can do. So, if youre looking to take a bold step in your beauty regime, this could be the time to do it as Dr Kashlan breaks down exactly what goes into PRP treatment and what you can expect from it.

PRP is a treatment that is really popular with my patients. Its earned the nickname of the Vampire Facial because it involves drawing the patients own blood and extracting the plasma from the blood and re-introducing the plasma to the skin. The platelets have within them growth factors which are proteins that stimulate different biochemical processes in the skin. Specifically, PRP is a great way to stimulate collagen production and improve the microcirculation to the skin. So typically, we draw a patients blood, process the blood to extract the plasma and then either inject or microneedle the plasma into the skin. We can also use PRP to stimulate hair growth on the scalp and I use it to improve dark circles under the eyes. The procedure is pain-free because we use a topical anaesthetic.

PRP is one of my favourite treatments because it improves the quality of the skin with very little downtime and is incredibly safe. Were using your own plasma so there is no foreign material and no risk of allergic reactions. PRP doesnt replace fillers or Botox because the result is different. Fillers are used to replace volume loss and Botox erases lines and wrinkles. PRP works in conjunction with these.

Like most skin treatments, you do want to avoid the sun before and after PRP for at least one week. Additionally, active skin irritations, like eczema or herpes infections are contraindications for PRP.

Typically, patients will have mild redness and swelling in the first 24-48 hours of PRP. Usually one week after treatment, patients will start to notice that their skin looks brighter and more even-toned and feels smoother. This is what we refer to as the PRP Glow. But the real benefits come from repeated sessions where you can see a reduction in pore size, wrinkles and fine lines.

I think deeper chemical peels like Dermamelan and laser-resurfacing procedures like the Erbium laser require a bit more bravery. These procedures are incredibly safe but they have a fair amount of downtime: redness, swelling, and peeling of the skin. This can require someone to either block out their professional and social calendar or be bold and continue their usual activities in spite of a little downtime.

I find that there is a higher level of appreciation for beauty in the Arab world than in the US. Both women and men in the Middle East recognize that taking care of their skin and enhancing their beauty is part of their overall health and wellness. There is a true sense of pride in looking after ones appearance. Because of this, there is definitely a heightened sense of awareness when it comes to the latest procedures when I compare my patients in the UAE to my patients in the US. In Dubai, my patients come in asking for the latest treatments by name. I would say my patients in Dubai are definitely braver and bolder when it comes to beauty and skincare. This can be a good thing or a bad thing. When treatments are done under the guidance of a qualified dermatologist or plastic surgeon, there is nothing to fear. Unfortunately, too often, I see patients who have been botched by other doctors who performed procedures that patients either didnt need or performed them incorrectly. So, I always encourage people to be cautious and to do their research before undergoing any cosmetic procedure.

Images: Getty

See the original post:
Everything you need to know about the Kim Kardashian vampire facial - Emirates Woman

Interventional Pain Management Specialist Dr. Kaliq Chang with Atlantic Spine Center offers tips on emerging treatment using your body’s own cells -…

By adminOctober 10, 2020Platelet Rich Plasma Injections

Dr. Kaliq Chang

WEST ORANGE, N.J. (PRWEB) October 08, 2020

Among the wide array of treatments available for chronic back pain, one is emerging thats distinct because it uses your bodys own cells to help you heal. Its called PRP, or platelet-rich plasma.

With two decades of research largely supporting PRPs benefits for conditions such as shoulder and knee pain, growing evidence suggests the minimally invasive treatment can also safely improve highly common lower back pain, says Kaliq Chang, MD, of Atlantic Spine Center.

PRP Platelet-rich plasma treatment involves taking a small sample of your blood and placing it in a machine called a centrifuge, which separates blood components. The plasma, or liquid, part of your blood is then placed in a syringe and injected into the painful area of your back while a special x-ray helps pinpoint where its needed most, Dr. Chang explains.

Within weeks, PRP treatment often results in significantly less back pain and a greater ability to perform everyday activities, he says.

More and more patients with lingering low back pain are inquiring about PRP to help rid them of the problem, adds Dr. Chang, an interventional pain management specialist. While additional data is still needed, its great to be able to tell them that PRP is becoming yet another sturdy tool in our arsenal of treatments to help beat back pain.

How does PRP work? Blood contains many substances that help promote the bodys healing process, and PRP treatment was developed on this premise, Dr. Chang says. As the so-called building blocks of blood, platelets which also help form scabs on abrasions, for example contain chemicals known as growth factors that support healing.

Also in platelets are proteins that trigger stem cells which can change into any type of cell to move toward an injured area. Growth factors and proteins work together to repair damaged tissue and make new, healthy tissue, Dr. Chang explains.

While our bodies normally carry out wound healing naturally, PRP injections concentrate those restorative cells at just the place we need them and in larger amounts, he says. In the lower back, this means damaged areas around the spine receive a much-needed boost to speed healing.

Back conditions PRP can help PRP isnt ideal for all types of low back pain, but your doctor after a thorough exam and workup may decide its a worthy option. What types of back problems can PRP treatment benefit? Pain caused by:

Degenerative disc disease, which are worn-down vertebral discs Muscle strains Damaged ligaments and tendons Muscle fibrosis

Two or three PRP treatments spaced over several months are optimal and seem to improve pain and function in the lower back more than a single treatment, Dr. Chang notes.

After an injection, you can expect to have some mild soreness near the injection site that lasts for a few days. Since PRP works by stimulating your natural healing response, it generally takes a few weeks before you start seeing the benefits. Because PRP is derived from your own blood, you cannot reject the cells a clear advantage, Dr. Chang says.

PRP treatments may also be combined with other approaches, such as physical therapy, to maximize the feel-good effects.

Mounting research suggests PRP is a safe, fast and powerful way to help facilitate healing in a hardworking area of our body the lower back, Dr. Chang says. Were happy to have a new and exciting way to help patients get back to their everyday activities with less pain and more joy.

Atlantic Spine Center is a nationally recognized leader for endoscopic spine surgery with several locations in NJ and NYC. http://www.atlanticspinecenter.com, http://www.atlanticspinecenter.nyc

Kaliq Chang, MD, is an interventional pain management specialist, double board-certified in interventional pain management and anesthesiology, at Atlantic Spine Center.

Share article on social media or email:

See original here:
Interventional Pain Management Specialist Dr. Kaliq Chang with Atlantic Spine Center offers tips on emerging treatment using your body's own cells -...

Was the antibody cocktail used to treat President Trump developed using human embryonic stem cells? – CBS News 8

By adminOctober 10, 2020Stell Cell Research

Social media is buzzing with the claim President Trump, who is pro-life, used an antibody cocktail developed using human embryonic stem cells.

Editor's note Oct 8:Thursday News 8 received further clarification from Regeneron spokesperson, Alexander Bowie.

She says HEK293T (Human embryonic kidney 293 cells)were used to help evaluate the efficacy of antibodies that ultimately went into the antibody cocktail.

"These are not stem cells. We did not use human stem cells or human embryonic stem cells in the development of REGN-COV2.

Specifically, HEK293Ts were used to make pseudovirus that looks like the Spike protein of the SARS-CoV-2 virus, and this is used to test our antibodies ability to neutralize the virus. HEK293s are considered immortalized cells (again, not stem cells) and are a common and widespread tool in research labs. This cell line was originally derived by adenovirus transformation of human embryonic kidney cells in 1977. After this, it was further transformed at Stanford in the 80s with SV40 T-antigen (hence the T). HEK293T wasnt used in any other way, and fetal tissue was not used in this research."

The antibody cocktail used to treat President Donald Trump for COVID-19 is getting a lot of attention on social media.

Some users are claiming Regeneron - the company that developed the treatment - used human embryonic stem cells to create it, but is this true?

News 8 reached out to Regeneron for comment.

"This particular discovery program (regn-cov2) did not involve human stem cells or embryonic stem cells," wrote Regeneron spokesperson Alexandra Bowie in a statement.

So, where did that claim about human embryonic stem cells come from?

It appears to have developed from this statement Regeneron issued back in April 2020 regarding stem cell research:

"As is the case with many other science-focused biotechnology companies, Regeneron uses a wide variety of research tools and technologies to help discover and develop new therapeutics. stem cells are one such tool. the stem cells most commonly used at Regeneron are mouse embryonic stem cells and human blood stem cells. currently, there are limited research efforts employing human-induced pluripotent stem cell lines derived from adult human cells and human embryonic stem cells that are approved for research use by the national institutes of health and created solely through in vitro fertilization."

According to the American Association for the Advancement of Science, here's what the antibody cocktail used to treat the president is made of:

"One antibody comes from a human who had recovered from a SARS-COV-2 infection; a B cell that makes the antibody was harvested from the person's blood and the genes for the immune protein isolated and copied. The other antibody is from a mouse, which was engineered to have a human immune system, that had the spike protein injected into it."

Bowie also told News 8 the statement about stem cell research on its website reflects the company's general position on stem cell research, but does not mean human embryonic stem cells were used in creating the antibody cocktail used to treat the president.

Nevertheless, some said the company's position on using stem cells in general contradicts President Trump's pro-life stance and that of Supreme Court Nominee Amy Coney Barrett.

Editors Note:This story was originally posted as a VERIFY report.

Follow this link:
Was the antibody cocktail used to treat President Trump developed using human embryonic stem cells? - CBS News 8

AIVITA Biomedical’s Stem Cell Therapeutic in Vision Loss Published in Investigative Ophthalmology & Vision Science – BioSpace

By adminOctober 10, 2020Stell Cell Research

IRVINE, Calif., Oct. 9, 2020 /PRNewswire/ --AIVITA Biomedical Inc., a private biotechnology company developing personalized vaccines for the treatment of cancer and COVID-19, announced today the publication of the peer-reviewed manuscript, "Retina organoid transplants develop photoreceptors and improve visual function in RCS rats with RPE dysfunction,"in the journal Investigative Ophthalmology & Visual Science. The study, led by researchers at AIVITA Biomedical and the Sue & Bill Gross Stem Cell Research Center of the University of California, Irvine, used 3D-retina organoids generated from human stem cells developed by AIVITA to provide insight into the potential use of transplanted retina organoids as a therapeutic option for blinding diseases.

In the study, transplanted retina organoid sheets were examined to determine if human stem cell-derived photoreceptors coulddevelop, survive and function in vivo without the support of healthy retina pigment epithelium (RPE). Visual function was examined through a variety of tests, including optokinetic testing (OKT), electroretinogram (ERG), and superior colliculus (SC) brain recording. These tests concluded that retina organoid transplantations demonstrated significant improvement in visual function compared to non-surgery and sham surgery controls, supporting the application of AIVITA's stem cell technologies in visual disease therapeutics.

"Leveraging our expertise in stem cell growth and differentiation, I'm excited to see the promise of our technology platform in potential therapeutics for vision loss," said Hans Keirstead, Ph.D., chief executive officer of AIVITA and a contributing author to the paper. "To our knowledge, this study is the first to show that it's possible for photoreceptors derived from stem cells to survive and function after transplantation when a host has a dysfunctional RPE."

This work is supported by funding from the California Institute for Regenerative Medicine (CIRM) and National Institutes of Health (NIH).

About AIVITA Biomedical AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its therapeutic pipeline and commercial line of skin care products. All proceeds from the sale of AIVITA's skin care products support the treatment of people with cancer.

View original content to download multimedia:http://www.prnewswire.com/news-releases/aivita-biomedicals-stem-cell-therapeutic-in-vision-loss-published-in-investigative-ophthalmology--vision-science-301149208.html

SOURCE AIVITA Biomedical, Inc.

Link:
AIVITA Biomedical's Stem Cell Therapeutic in Vision Loss Published in Investigative Ophthalmology & Vision Science - BioSpace

Boise State engineers given the opportunity to send stem cell research into space – Boise State University The Arbiter Online

By adminOctober 10, 2020Stell Cell Research

Boise State engineers have been awarded $315,000 from the National Science Foundation (NSF) to launch stem cell research into space.

Alexander Regner, masters student in materials science engineering, has been working on stem cell research for nearly three years. Through Regners research, he has studied the health and maintenance of bone and bone marrow.

As you exercise and move, your bone marrow stimulates cells, which is a vital part of maintaining health, according to Regner.

Thats why exercise is so good for you. We know all of this contributes to health and maintenance, but we dont actually know what it looks like mechanically to these cells, Regner said.

Regner and his associates Gunes Uzer, assistant professor of mechanical and biomedical engineering, and Aykut Satici, assistant professor of mechanical and biomedical engineering, have created a model to mimic the bone marrow mechanical environment and analyze what kind of mechanical environment is causing the cells to react in certain ways.

Regner uses a computer simulation that matches a 3D printed physical sample. This allows Regner to understand what the mechanical environment looks like so they can correlate the mechanical environment to the cellular response.

Through this research, Regner asks the big question, is there a different mechanical environment generated due to changes in bone architecture?

Gunes and Satici looked at Regners research and wanted to bring it to a bigger audience. Their new goal was to determine how stem cell research can benefit Earth. According to Gunes, space travel tends to produce tissue types and cell behavior that is similar to aging. This aging happens over a matter of weeks in space, as opposed to a matter of years on Earth.

We take one of these bone cells and we age them for a year or two. But obviously, these bones have a shelf life, Gunes said. Maybe we can do that in space in three weeks and do the experiment in space. Maybe we can learn more about how the bone mechanical environment contributes to the aging process. Thats really the project, take Alexs work and send it to space.

Saticis contribution to this research is from a different perspective, robotics. According to Satici, there needs to be mechanical vibrations applied to particular cells. To accomplish this, there needs to be a robotic mechanism to perform that motion in a consistent matter.

Center for the Advancement of Science in Space (CASIS) holds a subcontract with the International Space Station along with the National Science Foundation (NSF). Each year, they ask the question, what type of research can we perform in space that can teach us something about Earth and improve advanced science on Earth?

Regner, Gunes and Satici argued that they cannot properly age experiments on Earth, and proposed that space could be a good platform for their research. They wrote a grant proposal for their research, what they have done in the past, what they plan to do and who is a part of the research team.

Regner, Gunes and Satici also work closely with the University of Texas, Rensselaer Polytechnic Institute and Space Tango to complete this research.

Through this extensive research, Regner, Satici and Gunes emphasize the importance of working hard to accomplish ones goals.

Just because its fun to do, doesnt mean you are going to learn it. You have to persevere and do the dirty work. Try to improve yourself with any resources you can get, Satici said.

Regner advocates for students to continuously work hard to help solve modern problems. There are a lot of job opportunities in the STEM field, and many jobs that may not require a STEM background at all, like politics.

A lot of our modern problems we are dealing with are multidisciplinary things. It requires the involvement of everyone. Space flight, for example, you need people to understand not only the mechanics but make sure were safe while were doing it, Regner said. [There are] a lot of problems we are facing in the middle age. If youre interested in helping solve them, there are so many different opportunities to get involved. If you want to go into politics, we need people to advocate for science in politics to make sure that we have adequate funding and focused goals for where we are going and what we are doing.

Gunes hopes students who want to get involved and achieve their goals will start with volunteer work.

Go to a lab youre interested in and say Hey, I want to do volunteering involving research. Before you know it you start getting your masters, your Ph.D., and then you become a scientist. If youre interested in [science] then stop thinking about it and do it, Gunes said.

Originally posted here:
Boise State engineers given the opportunity to send stem cell research into space - Boise State University The Arbiter Online

Stem Cell and Progenitor Cell-based Therapeutics Market Market Size, Share, Industry Report by Growt – PharmiWeb.com

By adminOctober 10, 2020Stell Cell Research

Latest published market study on Global Stem Cell and Progenitor Cell-based Therapeutics Market with + data Tables, Pie Chart, high level qualitative chapters & Graphs is available now to provide complete assessment of the Market highlighting evolving trends, Measures taken up by players, current-to-future scenario analysis and growth factors validated with Viewpoints extracted via Industry experts and Consultants.Stem Cell and Progenitor Cell-based Therapeutics Market presents point by point serious investigation including the market Share, Size, Future extension. This investigation classifies the worldwide Stem Cell and Progenitor Cell-based Therapeutics breakdown information by makers, area, type and applications, likewise examines the market drivers, openings and difficulties. The study breaks market by revenue and volume (wherever applicable) and price history to estimates size and trend analysis and identifying gaps and opportunities. Some are the players that are in coverage of the study are VitroBioPharma, ViaCyte, Inc., Vericel., U.S. Stem Cell, Inc., Stemedica Cell Technologies, Inc, etc.

Data Bridge Market Research analyses the Stem Cell and Progenitor Cell-based Therapeutics Market to grow at a CAGR of 9.4% in the above-mentioned forecast period. Increasing focus on stem research is anticipated to create new opportunity for the stem cell & progenitor cell based therapeutics market.

Download Free Exclusive Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this Industry@ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-stem-cell-and-progenitor-cell-based-therapeutics-market

Overview:

Increasing investment in the R&D and advancement in the stem cell based therapies is expected to enhance the market growth. Some of the other factors such as increasing public-private investments for advancement of stem cell therapies, development of infrastructure of stem cell banking & processing, and rising cases of Parkinson disease will affect the growth of this market.

Some of the factors such as improper guidelines associated with the product development and lack of skilled & trained professional for cell culture technology are hampering the growth of this market.

The Stem Cell and Progenitor Cell-based Therapeutics Market 2020 Document clearly explains what market definition, classifications, applications, engagements and market trends are for the Stem Cell and Progenitor Cell-based Therapeutics industry. The Global Stem Cell and Progenitor Cell-based Therapeutics Market Share analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. For each manufacturer covered, this report analyzes their Stem Cell and Progenitor Cell-based Therapeutics manufacturing sites, capacity, production, ex-factory price, and revenue and market share in global market. This report studies the industry abilities for each geographical region based on the customer purchasing patterns, macroeconomic parameters, development rate, and market demand and supply states. What is more, it determines the impact of buyers, substitutes, new entrants, competitors, and suppliers on the market.

According to this report Global Stem Cell and Progenitor Cell-based Therapeutics Market will rise from Covid-19 crisis at moderate growth rate during 2020 to 2027. Stem Cell and Progenitor Cell-based Therapeutics Market includes comprehensive information derived from depth study on Stem Cell and Progenitor Cell-based Therapeutics Industry historical and forecast market data. Global Stem Cell and Progenitor Cell-based Therapeutics Market Size To Expand moderately as the new developments in Stem Cell and Progenitor Cell-based Therapeutics and Impact of COVID19 over the forecast period 2020 to 2027.

TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT, GET FREE COVID-19 SAMPLE @ https://www.databridgemarketresearch.com/covid-19-impact/global-stem-cell-and-progenitor-cell-based-therapeutics-market

Stem Cell and Progenitor Cell-based Therapeutics Market report provides depth analysis of the market impact and new opportunities created by the COVID19/CORONA Virus pandemic. Report covers Stem Cell and Progenitor Cell-based Therapeutics Market report is helpful for strategists, marketers and senior management, And Key Players in Stem Cell and Progenitor Cell-based Therapeutics Industry.

The Global Stem Cell and Progenitor Cell-based Therapeutics segments and Market Data Break Down are illuminated below:

By Disease Type (Parkinson Disease, Huntington Disease)

By Applications (Tissue Engineering, Stem Cells, Gene Therapy, Drug Discovery, Nanotechnology)

By End- Users (Pharmaceutical and Biotechnology Industries, Hospitals, Research Institutes, Biotechnology Companies, Others)

The report can help to understand the market and strategize for business expansion accordingly. In the strategy analysis, it gives insights from marketing channel and market positioning to potential growth strategies, providing in-depth analysis for new entrants or exists competitors in the Stem Cell and Progenitor Cell-based Therapeutics industry. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. For each manufacturer covered, this report analyzes their Stem Cell and Progenitor Cell-based Therapeutics manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

List of TOP KEY PLAYERS in Stem Cell and Progenitor Cell-based Therapeutics Market Report are

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart) @ https://www.databridgemarketresearch.com/toc/?dbmr=global-stem-cell-and-progenitor-cell-based-therapeutics-market

Stem Cell and Progenitor Cell-based Therapeutics Industry 2020 Market Research Report provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector. This reports provides current status for Stem Cell and Progenitor Cell-based Therapeutics market forecast till 2027. Likely, the report also focuses on global major manufacturers of Stem Cell and Progenitor Cell-based Therapeutics market providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out.

Stem Cell and Progenitor Cell-based Therapeutics Report covers the manufacturers data, including: shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume and value, as well as price data.

Global Stem Cell & Progenitor Cell-Based Therapeutics Market Scope and Market Size

Stem cell & progenitor cell-based therapeutics market is segmented of the basis of disease type, application and end- users. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

On the basis of disease type, the stem cell & progenitor cell-based therapeutics market is segmented into Parkinson disease and Huntington disease.

The application segment of the stem cell & progenitor cell-based therapeutics market is divided into tissue engineering, stem cells, gene therapy, drug discovery, and nanotechnology.

On the basis of end- users, the stem cell & progenitor cell-based therapeutics market is segmented into pharmaceutical and biotechnology industries, hospitals, research institutes, biotechnology companies and others.

For More Information or Query or Customization Before Buying, Visit @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-stem-cell-and-progenitor-cell-based-therapeutics-market

The report offers in-depth assessment of the growth and other aspects of the Stem Cell and Progenitor Cell-based Therapeutics market in important countries (regions), including:

What the Stem Cell and Progenitor Cell-based Therapeutics Market Report Contains:

Organization profiles of the main rivals alongside their strategic activities and market shares.

Assurance and examination of the macro and microeconomic variables that influence the Global Market, as per the regional analysis.

Market Overview for the Global Stem Cell and Progenitor Cell-based Therapeutics Market and the identification of the market elements, including development drivers, limitations, difficulties, and potential opportunities for the market.

Assurance of various elements in charge of changing the market scene, rising future chances and assurance of driving players, which can influence the market on a territorial scale.

Market analysis for the Global Stem Cell and Progenitor Cell-based Therapeutics Market, with an aggressive scene and geographic examination on a worldwide and territorial scale.

Order a Complete Research Report Enabled with COVID-19 Impact Coverage @ https://www.databridgemarketresearch.com/checkout/buy/singleuser/global-stem-cell-and-progenitor-cell-based-therapeutics-market

With tables and figures helping analyze worldwide Global Stem Cell and Progenitor Cell-based Therapeutics Market Forecast provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

The content of the study subjects includes a total of 15 CHAPTERS:

Chapter 1, to describe Stem Cell and Progenitor Cell-based Therapeutics product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Stem Cell and Progenitor Cell-based Therapeutics, with price, sales, revenue and global market share of Stem Cell and Progenitor Cell-based Therapeutics in 2018 and 2019.

Chapter 3, the Stem Cell and Progenitor Cell-based Therapeutics competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Stem Cell and Progenitor Cell-based Therapeutics breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2010 to 2020.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2010 to 2020.

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2010 to 2020.

Chapter 12, Stem Cell and Progenitor Cell-based Therapeutics market forecast, by regions, type and application, with sales and revenue, from 2020 to 2027.

Chapter 13, 14 and 15, to describe Stem Cell and Progenitor Cell-based Therapeutics sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Our Other Reports:-

Exosome Therapeutic Market Size, 2020-New Technological Change Helping Market, Application, Driver, Trends, Share and Forecasts by 2027

Healthcare Fraud Detection Market 2020-Global Technology, Development, Trends and Comprehensive Study: IBM, Optum, COTIVITI, McKesson, Wipro

Occupational Therapy Market 2020 Size, Share, Global Trends, Development Status, Opportunities, Competitive Landscape-WebPT, Premise Health, Net Health, CLINICIENT

Customization Service of the Report:

Data Bridge Market Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team (Corporatesales@databridgemarketresearch.com), who will guarantee you to get a report that suits your necessities.

AboutDataBridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today! Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:Corporatesales@databridgemarketresearch.com

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.

Visit link:
Stem Cell and Progenitor Cell-based Therapeutics Market Market Size, Share, Industry Report by Growt - PharmiWeb.com